Loading
A phase 2 trial of AST-301 in gastric & gastro-oesophageal junction cancer, run by Aston Sci. Inc., active and no longer recruiting.
Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer is a phase 2 interventional study registered as NCT05771584 by Aston Sci. Inc., with 24 participants enrolled, started 2023-07-04 and due to reach its primary completion in 2027-02-09. Interventions recorded: AST-301 and rhuGM-CSF.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares HER2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares HER2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares HER2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares HER2-positive gastric cancer and the tag pipeline.
Shares HER2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares HER2-positive gastric cancer, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/